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Abstract
Eosinophilic esophagitis also known as asthma of the esophagus is a food-related 
allergic disorder of the esophagus widely distributed all over the world. The inci-
dence and prevalence of eosinophilic esophagitis have been increasing over the last 
few decades. The pathogenesis of this entity is now better understood and three 
distinct endotypes have been defined for better management strategy. Diagnosis is 
made on the basis of clinical symptoms followed by endoscopy with biopsy. Drugs, 
diet and endoscopic dilation are the current modalities of treatment. IL-4 and IL-13 
inhibitors have been found to be promising in clinical trials.
Keywords: eosinophilic esophagitis, asthma of esophagus, dysphagia, food bolus 
impaction, esophageal eosinophilia, esophageal stricture
1. Introduction
Eosinophilic esophagitis (EoE) is a chronic immune/allergy mediated disease of 
the esophagus characterized by esophageal eosinophilia (presence of ≥15 eosino-
phils/high power field in at least 1 esophageal biopsy.), esophageal dysfunction 
(dysphagia, food impaction) and characteristic endoscopic features [1]. To establish 
the diagnosis, other causes of esophageal eosinophilia must be excluded. In 1989, 
EoE was first recognized as a distinct clinical entity by Attwood et al. [2]. Now there 
is an epidemic of EoE in the western world. EoE is increasingly being recognized 
and diagnosed in our clinical practice both in the acute and chronic settings. EoE 
has distinct clinical epitopes, diagnostic and treatment protocol. The epidemiology, 
pathogenesis, pathology, clinical feature, investigations, management and progno-
sis will be described in this chapter.
2. Epidemiology
The disease is more common in Caucasian population with a male to female ratio 
of 3:1 [3]. Eosinophilic esophagitis has also been seen in African Americans, Asians 
and Hispanic population. The disease is increasingly being recognized over the last 
few decades. The current incidence is 5 to 10 cases per 100,000 population, and the 
current prevalence is 0.5 to 1 case per 1000 population in North America, Europe 
and Australia [4]. The disease can affect both children and adults. In adults, EoE is 
more commonly seen in males than in females and the average age of patients with 
EoE is between 30 and 50 years. Most of the patients with EoE have personal history 
of allergic disorders like bronchial asthma, allergic rhinitis, allergic conjunctivitis or 
food allergy.





Exposure of the esophagus to food and aeroallergens in genetically predisposed 
individuals may initiate the process of eosinophilic esophagitis although the exact 
mechanism is currently unknown [5]. Foods most commonly implicated in EoE are: 
Milk, egg, wheat, soy, peanuts, beans, rye and beef. Genome wide association analysis 
(GWAS) suggested that CAPN14 at 2p23 locus is upregulated after epithelial expo-
sure to interleukin (IL) 13 [6]. Recently, epithelial derived cytokine thymic stromal 
lymphopoietin (TSLP) gene at 5q22 locus has been identified as a candidate gene in 
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a multicenter GWAS. There is an increased expression of TSLP in patients with EoE. 
TSLP activates dendritic cells (antigen presenting cells). Food allergen is initially 
recognized by antigen presenting cells which differentiate CD4 cells into TH1 cells 
and TH2 cells. TH1 cells secrete interferon γ (IFN-Υ) and transforming growth factor β 
(TGF-β). TH2 cells secrete IL 4, IL 5 and IL 13. There is also single nucleotide poly-
morphism (SNP) in this TSLP receptor gene in male patients with EoE. This gene is 
found on the pseudoautosomal region on Xp22.3 and Yp11.3. This finding may explain 
increased prevalence of EoE in male patients. There is also a suggestion of second 
hit for the development of EoE. Toll like receptor 3 (TLR 3) can recognize double-
stranded RNA (found in some viruses) and can induce TSLP [7]. IL 5 is responsible 
for eosinophilic infiltration, growth and survival. Eosinophils secrete various inflam-
matory cytokines and chemokines including macrophage migration inhibitory factor 
(MMIF), tumor necrosis factor (TNF), granulocyte monocyte colony stimulating 
factors (GMCSF) and toxic granules [8]. TGF-β1 is a profibrotic molecule and helps in 
remodeling of the esophagus in EoE. This may lead to esophageal luminal narrowing, 
stricture formation and dysmotility. Eotaxin 3 is a strong chemotactic agent for esopha-
geal eosinophilia. A single nucleotide polymorphism in the human eotaxin-3 gene was 
associated with disease susceptibility. IL 4 and IL 13 secreted by TH2 can stimulate 
eotaxin 3. In telomerase immortalized esophageal squamous cells of EoE patients, IL 4 
stimulated eotaxin 3 secretion was blocked by PPI  omeprazole and lansoprazole [9]. 
This may explain PPI responsiveness of esophageal eosinophilia. Twin and family 
studies suggest that there is not only increased prevalence of EoE in male sex but also 
in monozygotic twins and other family member [10]. The pathogenesis of EoE is 
shown in a flow diagram in Figure 1.
4. Pathology
The major features (Figure 2) include infiltration of numerous eosinophils 
(usually >15 per high power field) into the squamous epithelium, layering of 
eosinophils on the surface layer and eosinophilic microabscess formation (clusters 
of ≥4 eosinophils). Often necrotic squamous cells are also seen on the surface layer 
[11]. Minor features include chronic inflammatory infiltrate into the lamina propria 
with fibrosis of the lamina propria [12], hyperplasia of muscular layers and basal 
epithelial cells with lengthening of lamina propria papillae, and intercellular edema. 
One study showed plenty of IgG4 containing plasma cells in the lamina propria [13]. 
The pathological changes are patchy in distribution, and generally affect the whole 
Figure 2. 
HE staining showing esophageal eosinophilia.
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length of the esophagus. None of the histologic findings is specific for eosinophilic 
esophagitis. Esophageal eosinophilia can be found in a variety of disorders including 
gastroesophageal reflux disease (GERD), eosinophilic gastroenteritis, hypereosino-
philic syndrome, Crohn’s disease, connective tissue diseases, drug hypersensitivity, 
parasitic and fungal infections and achalasia. In clinical practice, the real challenge 
comes to differentiate EoE from GERD [14]. Eosinophilic degranulation is seen more 
profoundly in EoE than in GERD biopsy specimen [15]. In EoE, the eosinophilic 
inflammation extends beyond mucosa into the submucosa and muscularis propria.
5. Clinical feature
Patients with eosinophilic esophagitis generally present with solid food dyspha-
gia or esophageal food impaction requiring endoscopic removal of food bolus as an 
emergency case [16]. In one study, EoE was found in 9% of all cases of esophageal 
food impaction [17]. Commonly, the diagnosis is suspected after a first episode of 
esophageal food impaction and biopsy showing esophageal eosinophilia. Less com-
monly, patients present with heartburn and chest pain mimicking gastroesophageal 
reflux disease. One study found that gender was an important factor in the initial 
clinical presentation of eosinophilic esophagitis. Men presented with dysphagia 
and esophageal food impaction more commonly than women. Women presented 
with heartburn and chest pain more commonly than men [18]. Diffuse narrowing 
of the esophageal lumen has been seen in clinical practice as a result of chronic 
inflammation and fibrosis. Esophageal mucosa is friable in EoE, and as a result, 
esophageal mucosal tear and esophageal perforation can occur during endoscopic 
esophageal foreign body removal and during esophageal stricture dilation [19]. As 
aeroallergens play an important role in the pathogenesis, EoE is diagnosed more 
frequently when the environmental pollen counts (grass, trees and weeds) are high; 
the highest percentage of EoE occurs in the Spring and the lowest percentage in the 
Winter [20]. The diagnosis of EoE is not increased in the summer months [21].
6. Diagnostic tests
6.1 Laboratory (lab) tests
There is no single Lab test that can support the diagnosis of EoE. Mild peripheral 
eosinophilia may or may not be present. Peripheral eosinophilia, elevated serum 
eosinophil derived neurotoxin and eotaxin 3 (CCL26) may have the potential to act 
as a biomarker for monitoring EoE [22].
6.2 Endoscopy
The esophageal mucosa may look normal in 7–10% of cases of EoE [23]. A 
variety of non specific features of inflammation can be seen in EoE during endos-
copy. The five major endoscopic features of EoE as per EoE endoscopic reference 
score (EREFS) are edema, rings (Figure 3), exudates, furrows and strictures [24]. 
Edema is identified by loss of vascular markings and mucosal pallor. Transient 
concentric rings or trachealization may indicate esophageal longitudinal muscle 
contraction [25] and fixed rings may indicate fibrous stricture formation due to 
tissue remodeling. Exudates or white spots or white plaques may mimic candida 
esophagitis, histologically they are eosinophilic microabscesses. Furrows are vertical 
lines running parallel to the axis of the esophagus probably due to epithelial edema. 
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Chronic eosinophilic esophagitis may lead to long segment or short segment stric-
ture. Narrow caliber esophagus due to luminal narrowing of most of the esophagus is 
infrequently seen in EoE. Crepe paper esophagus occurs due to esophageal mucosal 
fragility and is recognized by a mucosal tear that occurs during passage of a diag-
nostic endoscope but neither during endoscope withdrawal nor after esophageal 
dilation. Although more than one of the above endoscopic findings can be seen in 
the same patient, none of them is specific for EoE. Recently, esophageal “pull” sign 
(substantial resistance and mucosal tenting during pulling of the biopsy forcep) was 
found to be highly specific and responsive to successful therapy in EoE patients [26].
Current recommendation is to take at least 2 to 4 biopsies from both proximal and 
distal halves of the esophagus (5 cm above GE junction) and also to take targeted biop-
sies from abnormal mucosa, i.e., exudates, rings, edema, furrows and strictures. Gastric 
and duodenal biopsies should also be taken to evaluate eosinophilic gastroenteritis.
7. Barium swallow
Imaging studies are generally not done to diagnose EoE. Barium swallow may show 
normal esophagus. Sometimes featureless narrow caliber esophagus, ringed esophagus, 
and isolated esophageal stricture are seen in EoE. But none is pathognomonic of EoE.
8. Esophageal manometry
Generally normal peristalsis is seen in EoE. Prolonged esophageal manometry and 
pH metry showed ineffective esophageal peristalsis in children with EoE [27]. Twenty-
four hours pH study would be normal in EoE unless there is coexistent GERD.
9. Echoendoscopy
Echoendoscopy may show hypoechogenesity and thickening of all the layers of 
the esophageal wall due to inflammation and edema [28].
Figure 3. 
Endoscopy showing multiple esophageal rings.
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10. Endotyping
In 2018, Consortium of Eosinophilic Gastrointestinal Disease Researchers 
analyzed endoscopic and histological features in patients with EoE using 
eosinophilic esophagitis diagnostic panel (EDP) which is a set of 96 informative 
transcripts. The EoE endoscopic reference score (EREFS), EoE histology scoring 
system (HSS), quantification of esophageal eosinophils and molecular features 
were assessed. The EDP identified clear signature of 3 distinct endotypes of 
EoE [29]:
1. Endotype 1 (EoEe1): It is the mild endotype. It is associated with relatively 
mild endoscopic (almost normal appearing esophagus), histologic and mo-
lecular changes. It is inversely associated with history of esophageal dilation. It 
represents 35% of all EoE patients.
2. Endotype 2 (EoEe2): It is the Inflammatory and steroid-refractory endotype. 
It is associated with esophagitis due to the highest expression of inflammatory 
cytokines. It has also the highest expression of steroid responding genes. It 
represents 29% of all EoE patients.
3. Endotype 3: It is the fibrostenotic and adult onset endotype. It is associated 
with narrow-caliber esophagus. It has the highest degree of endoscopic and 
histological severity and the lowest expression of epithelial differentiation 
genes. It represents 36% of all EoE patients.
10.1 Diagnostic criteria of EoE
1. Symptoms of esophageal dysfunction such as dysphagia, food impaction.
2. Characteristic endoscopic features: edema, rings, exudates, furrows and stric-
tures (EREFS).
3. Esophageal eosinophilia i.e. > 15 eosinophils per high power field.
4. Exclusion of other causes of esophageal eosinophilia.
11. Management
Firm diagnosis of EoE is essential before offering any treatment. 
Symptomatic esophageal eosinophilia is now considered as EoE when other 
secondary/non-EoE causes are excluded [30]. Few years ago, the term proton 
pump inhibitor responsive esophageal eosinophilia (PPI REE) was used [31] but 
EoE and PPI REE are indistinguishable clinically, endoscopically and pathologi-
cally. The term PPI-REE is no longer used at the present time. The main aim of 
treatment of EoE is not only clinical improvement but also histological improve-
ment to prevent development of esophageal stricture. In 2020, the American 
Gastroenterology Association (AGA) and the Joint Task Force on Allergy-
Immunology Practice Parameters (JTF) recommended certain guidelines on the 
management of EoE [32]. Currently, drugs, diet and dilation are the three main 
modalities of treatment of EoE.
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PPI is now used as the first-line treatment of EoE. In adults patients treated with 
PPI, symptomatic improvement can range from 25–80% and histological remission 
from 33–61% [33]. As mentioned before, PPI can block IL-4 stimulated eotaxin-3 
secretion and thus can inhibit eosinophil recruitment from blood into the esophageal 
tissue [34]. Significant improvement of dysphagia can occur in few days’ time. PPI 
can also be used as an adjunctive therapy when patients with EoE require esophageal 
dilation. Richter et al. found that esophageal eosinophilia was decreased in patients 
who received combination of PPI and esophageal dilation but not in patients who had 
esophageal dilation alone [35]. Finally, PPI can also restore the esophageal mucosal bar-
rier function in patients with EoE and thus can inhibit the entry of aeroallergens into 
the esophageal mucosa [36]. It is author’s opinion that in endotype 1, full dose of PPI 
once a day or low dose PPI twice a day should be initiated. Patients should be evaluated 
for symptomatic/clinical response after 4 weeks. At that time, there will be 2 groups:
1. Non-responders or inadequate clinical responders: dose of the PPI should be 
doubled and the patient should be evaluated again after 4 weeks. If there is no 
improvement of clinical response after 4 weeks, alternate therapy should be 
considered.
2. Responders or adequate clinical responders: same dose of PPI should be con-
tinued for another 4 weeks. Then the dose of PPI should be lowered to main-
tain controlling patient’s symptoms.
A recent study found that in endotype 2, continuation of PPI therapy for at least 
12 weeks had greater chance of inducing remission of EoE whereas in endotype 3, there 
was less responsiveness to PPI therapy both in the beginning and in the long run [37].
12.2 Topical glucocorticosteroids
Have become the second line medications for the treatment of EoE. Fluticasone 
metered dose inhaler 880 microgram puffed directly into the mouth without 
breathing and then dry swallowed twice a day for 6 to 8 weeks has been found to be 
effective in reducing symptoms and esophageal eosinophilia in 50 to 80% of cases 
[38, 39]. Patients are advised not to take any food or drink or rinse their mouth for 
half an hour to prevent the medication from washing off the esophageal mucosa. 
The maximal anti-inflammatory effect is found in proximal esophagus. Oral vis-
cous budesonide (OVB) 1 mg twice a day also decreases dysphagia and esophageal 
eosinophilia. OVB is easy to swallow, more mucoadherent and is made by mixing 
aqueous solution of budesonide (1 mg/2 mL) with the sugar substitute sucralose 
(5 g), chocolate syrup or honey [40]. Both forms of topical corticosteroids are more 
effective in histologic improvement than symptomatic improvement. Only 1% of 
the topical steroid is absorbed, so systemic side effects are extremely rare although 
oral and esophageal candidiasis can occur in up to one third of the time and herpes 
simplex esophagitis have been reported rarely.
Topical steroid is generally given for 8 weeks. If that fails, prolonged or higher 
doses of topical steroids or systemic steroids or dietary treatment or esophageal 
dilation should be tried to get symptomatic improvement. The AGA/JTF suggests 
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continuation of topical glucocortisteroids as maintenance therapy in patients with 
EoE in remission after short-term use of topical glucocoticosteroids.
13. Diet
Dietary therapy is very effective in the management of EoE. It can be used as an 
initial therapy or when other modalities of treatments fail. Dietary therapy depends 
on the resources available and can be expensive. As the dietary food allergen is 
removed, dietary therapy is very effective in inducing and maintaining clinico-
pathological remission. The three ways of dietary modification include:
1. Elemental diet: Amino acid based formula to remove food allergens. This 
therapy when given for a minimum of 6 weeks did both symptomatic and his-
tologic improvement (95% and 98% respectively) in EoE patients [41]. But the 
amino acid formula is expensive and unpalatable which affect patients’ quality 
of life, especially in children.
2. Six food group elimination diet (SFGED): The most common food allergens in 
EoE include milk, egg, wheat, soy, peanuts/tree nuts and sea food (fish/shell-
fish). Significant clinical and histological (74%) improvement occurred in EoE 
patients (children) when they were on this SFGED [42]. Another study showed 
four food group elimination diet (FFGED) which excludes milk, egg, wheat 
and legumes, when given for 6 weeks, clinicopathological remission occurred 
in 54% of adult EoE patient [43], and
3. Targeted or tailored elimination diet: This therapy is guided by detection of 
food allergens by skin prick/patch tests and blood tests. These tests can be not 
only time consuming but also can give false positive and false negative results. 
This therapy is offered as per the preference of the patient. Sixty-eight percent 
of EoE patients had symptomatic improvement on targeted therapy [44]. A 
dietitian interested in food allergies and EoE should be consulted. An Allergist 
should also be involved to find out the allergens triggering EoE. Food challenge 
by introducing one food or food group every 4 to 6 weeks should be offered. 
If the patient is allergic to food, there will be recurrence of symptoms and 
esophageal eosinophilia [45]. The AGA/JTF suggests using elemental diet or 
SFGED or testing based elimination diet over no treatment.
14. Systemic steroids
Oral methylprednisolone induced marked clinical and histological improvement in 
pediatric EoE patients [46]. Because of systemic side effects, this therapy is reserved 
when other therapeutic interventions fail. Steroids work by reducing the synthesis of 
eota xin 3, IL 5 and GMCSF, and inducing the apoptosis of eosinophils. But recurrence 
of the EoE occurs after withdrawal of the steroids. The AGA/JTF suggests topical 
glucocorticosteroids rather than systemic steroids should be used in patients with EoE.
15. Immunomodulators
Azathiopurine and 6 mercaptopurine induced and maintained clinical and 
histological remission in steroid dependent EoE patients in a case series [47]. They 
are not currently recommended for routine clinical use in EoE.
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16. Mast cell stabilizers
In a small case series, Cromolyn sodium failed to show any clinical or histologic 
improvement in EoE patients [48].
17. Leukotriene inhibitors
Montelukast is an eosinophil stabilizing agent. It improved clinical symptoms in 
EoE but there was no histological improvement [49].
17.1 IL-4 inhibitor
Dupilumab is an interleukin-4 receptor antagonist/monoclonal antibody. It has 
been found to be effective in improving dysphagia and esophageal eosinophilia 
(intraepithelial eosinophil count of ≤6 eosinophils per high-power field) in a double 
blind, placebo-controlled, pivotal phase 3 trial (Part A) that evaluated its efficacy in 
81 patients aged ≥12 years with EoE. Dupilumab was granted Breakthrough Therapy 
designation by the FDA (Food and Drug Administration, USA) in September, 2020 
for the treatment of the patients aged ≥12 years with EoE [50]. This designation 
would allow expedited review of dupilumab for the FDA approval.
17.2 IL-13 inhibitor
RPC4046 (a humanized monoclonal antibody against IL13) was found to improve 
dysphagia, and reduce histologic and endoscopic features compared with placebo in a 
phase II trial. The medication was also found to be safe and well tolerated [51].
17.3 IL-5 inhibitor
Anti IL 5 antibody has been studied in both pediatric and adult patients with 
EoE. Mepolizumab significantly reduced esophageal eosinophilia but there was 
minimum symptomatic improvement [52]. Reslizumab also improved esophageal 
eosinophilia in EoE but there was no difference in clinical improvement in 
comparison to placebo [53, 54].
17.4 Macrophage migration inhibitory factor (MIF)
Macrophage migration inhibitory factor (MIF) is overexpressed in the 
esophageal mucosa of EoE patients. Recently, in the mice model of EoE, early 
administration a drug that blocked the action of MIF prevented eosinophilic 
infiltration in the esophagus. This study can lead to a novel therapy in future if MIF 
effect can be blocked in EoE patients [55].
The medications investigated for the treatment of EoE can be grouped as follows:
• Medications with proven effectiveness: PPI, topical glucocorticoids, systemic 
steroids. Immunomodulators.
• Medications under development: IL-4 inhibitor, IL-13 inhibitor, MIF.
• Medications with proven ineffectiveness: mast cell stabilizers, leukotriene 
inhibitors, IL-5 inhibitors.
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18. Endoscopic treatment
Esophageal dilation has definitive role in the management of EoE. Dilation is 
not indicated in patients with normal caliber esophagus and signs of inflammation 
during endoscopy [56]. It is very effective in symptomatic esophageal stricture 
(esophageal diameter < 10 mm), long segment narrowing and narrow caliber 
esophagus. This modality of treatment improves dysphagia and quality of life but 
does not reduce esophageal eosinophilia [57]. Either hydrostatic balloon dilation 
or wire guided bougie dilation can be done. Esophageal diameter should be 15 to 
18 mm to relieve dysphagia. Patients may need multiple sessions to achieve this. 
There is an increased risk of mucosal tear causing post dilation chest pain for 
several days [58]. Although initially thought that EoE patients carry higher risk of 
perforation after esophageal dilation, systematic review did not show any higher 
risk of perforation (0.1%) in this group of patients [59].
18.1 Endoscopic surveillance
Currently there is no guideline when surveillance endoscopy should be done 
in EoE patients who have achieved remission. In clinical practice, endoscopic 
and histologic assessment should be done 6 to 8 weeks after initiation or change 
of treatment to evaluate the efficacy of the treatment. When the disease is under 
remission, less frequent assessment/surveillance is done on a yearly basis or less 
frequently depending on the clinical scenario and the clinician.
18.2 Prognosis
As mentioned earlier, EoE is a chronic inflammatory disease of the esophagus. 
The inflammation leads to remodeling, fibrosis and stricture. Fortunately, no 
case of esophageal malignancy has been reported in EoE. Patients are generally 
diagnosed after several years of their symptoms. Although symptomatic 
improvement occurs after treatment, recurrence is common after discontinuation 
of treatment. So maintenance therapy is needed to prevent recurrences. At the 
present time there is no head to head study to suggest the best maintenance 
treatment. Continuation of PPI, swallowed glucocorticosteroid and/or dietary 
therapy should be done in all EoE patients particularly in those with history of food 
impaction, dysphagia, esophageal stricture, and in those with rapid symptomatic 
and histologic relapse following initial treatment.
19. Summary
EoE has become a common clinical entity in patients with dysphagia and 
esophageal food impaction. Although the disease is more common in young male 
patients with allergic disorders, any person can get affected. High degree of suspi-
cion is essential to diagnose this disease. So multiple proximal and distal esophageal 
biopsies should be taken in EoE suggestive mucosa (EREFS) and even in normal 
looking mucosa. Other causes of esophageal eosinophilia particularly GERD, 
eosinophilic gastroenteritis and hypereosinophilic syndrome should be considered. 
The morbidity can be managed and long-term complications can be prevented by a 
multidisciplinary team which includes gastroenterologists, pathologists, allergists 
and dietitians. Patients with EoE should be given PPI therapy or topical glucocor-
ticosteroids for 8 to 12 wk. If there is no clinicoopathological improvement i.e., in 
treatment-resistant cases, esophageal dilation should be offered [60]. Esophageal 
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dilation in combination with PPI therapy or topical glucocorticosteroid therapy 
should be offered to patients with esophageal strictures and narrow caliber lumen. 
Lowest effective dose of PPI therapy or topical glucocorticosteroid should be 
continued to all EoE patients as maintenance therapy to reduce progression of the 
disease and relapse. Patients with EoE should be referred to the dietitians interested 
in food allergies and EoE patients. The AGA/JTF recommends using immunomodu-
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